Replimune Group, Inc. — Form SCHEDULE 13D/A
Filed August 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Baker Bros. Advisors LP filed an amended Schedule 13D/A on August 11, 2026 regarding its beneficial ownership stake in Replimune Group, Inc. The filing document itself contains no specific details on share count, percentage ownership, dollar amounts, or the nature of changes to the previously reported position. The specific amendments and current ownership metrics are not disclosed in the provided filing text.
Why this rating
Amendment alone is routine disclosure; lacks concrete specifics (shares, %, value) needed to assess magnitude. Baker Bros. is known large biotech investor; absent revised ownership data, cannot determine if this represents material change relative to $234.5M market cap.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.